Market Opportunities Use of GLP-1 Therapies in Metabolic Dysfunction and Development of Next-generation Oral & Combination Incretin Therapies Offer Growth Opportunities to Market Players The growing clinical potential of GLP-1 receptor agonists in treating MASH is creating significant opportunities for pharmaceutical manufacturers and biotechnology companies
Virucidal, antiviral and immunomodulatory activities of -escin and Aesculus hippocastanum extract
As in the prior GLP-1 trials reviewed, the GI side effects early that include vomiting, diarrhea, nausea, and constipation, occur in about half of the participants with initial dosing
If you notice swelling in your face, lips, or tongue, a severe rash, difficulty breathing, or a fast heartbeat, seek medical help immediately